SynthesisPediatric dermatology2025
Psychiatric Comorbidities and Quality-of-Life Burden in Pediatric Patients With Vitiligo: A Systematic Review and Meta-Analysis.
Synthesis in Pediatric dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Psychiatric Comorbidities and Quality-of-Life Burden in Pediatric Patients With Vitiligo: A Systematic Review and Meta-Analysis.Pediatric dermatology · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVitiligo is an autoimmune condition that causes depigmented skin patches, often leading to challenges such as stigma, bullying, and poor self-esteem in pediatric populations. These challenges may contribute to psychiatric comorbidities and impaired quality of life (QoL). Pediatric-specific data remain limited.
objectivesTo synthesize current evidence on psychiatric comorbidities and QoL outcomes in pediatric vitiligo and identify factors associated with increased psychosocial burden.
methodsPubMed, Embase, and MEDLINE were systematically searched through March 15, 2025, for primary English-language studies involving patients aged 0-18 years with vitiligo and validated psychiatric or QoL outcomes. Study quality was assessed using Oxford Centre for Evidence-Based Medicine Levels of Evidence. Meta-analyses were performed where possible, with 95% confidence intervals and I
resultsFourteen studies (n = 1576) were included. Pooled means for depression (CDI: 9.93) and anxiety scores (STAI-State: 37.07; STAI-Trait: 38.27) did not exceed thresholds for probable clinical diagnosis, though heterogeneity was considerable. Pooled means for QoL burden (CDLQI: 3.00; PedsQL: 80.55) suggested mild-to-moderate QoL impairment. Multiple individual comparative studies reported greater psychiatric symptom burden and higher prevalence of depression and anxiety among vitiligo patients versus controls. Subgroup findings from selected studies also suggested worse QoL in adolescents and those with extensive or visible lesions.
conclusionsPediatric vitiligo is associated with elevated psychiatric comorbidity prevalence, symptom burden, and mild-to-moderate QoL impairment among included studies. These findings highlight the need for clinicians to integrate psychosocial assessment into routine care. Current evidence further emphasizes incorporating routine mental health screening and multidisciplinary support into pediatric dermatology practice for children with vitiligo, although conclusions are restricted by limited and heterogeneous data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.